Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial

OBJECTIVES: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Horton, Sarah, Dumitru, Raluca Bianca, Naraghi, Kamran, van der Heijde, Désirée, Wakefield, Richard J, Hensor, Elizabeth M A, Buch, Maya H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147179/
https://www.ncbi.nlm.nih.gov/pubmed/31996367
http://dx.doi.org/10.1136/annrheumdis-2019-216539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147179/
https://www.ncbi.nlm.nih.gov/pubmed/31996367
http://dx.doi.org/10.1136/annrheumdis-2019-216539

Ejemplares similares